Skip to main content

Table 3 Differences in characteristics of the SELECT and DECISION trials (bold text/shaded cells)

From: A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine

  1. DTC Differentiated thyroid cancer, ECOG Eastern Cooperative Oncology Group, n/a Not applicable, NR Not reported, PS Performance status, TKI Tyrosine kinase inhibitor
  2. Sources: Eisai Ltd. 2017 [24, 26], EPAR for lenvatinib [27, 51] and appendix to Bayer HealthCare 2017 [25]
  3. Text in bold relates to the most notable differences between placebo arms and shaded cells the most notable differences between trials in any arm